SIDLEY AUSTIN LLP

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Income

$96.9M

Filings

2,850

Unique Clients

Active Period

1999–2026

Lobbying Income by Year

Registrant-reported income from clients on LDA filings

Year	Lobbying Income	Filings	Clients
2026	$700,000	68	23
2025	$2,020,000	86	23
2024	$1,825,000	91	26
2023	$2,505,000	95	27
2022	$5,215,000	133	34
2021	$6,275,000	145	38
2020	$7,030,000	156	41
2019	$4,255,000	123	32
2018	$4,170,000	132	36
2017	$4,580,000	130	38
2016	$4,715,000	131	35
2015	$3,475,000	104	28
2014	$2,670,000	79	21
2013	$2,460,000	94	24
2012	$2,451,000	94	23
2011	$3,290,000	71	21
2010	$4,505,000	130	41
2009	$6,350,000	170	44
2008	$5,890,000	191	54
2007	$11,240,000	161	51
2006	$3,320,000	91	49
2005	$3,090,000	96	51
2004	$1,360,000	76	46
2003	$1,870,000	58	30
2002	$430,000	62	26
2001	$280,000	20	12
2000	$200,000	32	13
1999	$682,257	31	15

Top Clients

Largest clients by registrant-reported income

Client	Reported Income	Filings	Period
MASTERCARD INTERNATIONAL INCORPORATED	$12,360,000	93	1999–2026
HIKVISION, USA INC.	$11,765,000	27	2018–2022
GRIFOLS INC	$8,010,000	33	2005–2013
SUNOVION PHARMACEUTICALS INC	$5,490,000	64	2004–2020
ILLUMINA, INC.	$4,625,000	17	2021–2024
BAYER HEALTHCARE	$3,025,000	39	2004–2014
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA	$2,820,000	47	2002–2012
INTREXON CORPORATION	$2,790,000	25	2016–2021
VIFOR PHARMA LTD	$2,060,000	56	2012–2025
MEDELA LLC	$1,570,000	31	2017–2024
AQUABOUNTY TECHNOLOGIES, INC.	$1,430,000	24	2019–2024
GENENTECH	$1,420,000	32	2002–2010
NRG ENERGY	$1,340,000	20	2013–2017
BIOTECHNOLOGY INDUSTRY ORGANIZATION	$1,260,000	34	2002–2010
PURDUE PHARMA L.P.	$1,170,000	44	2007–2019
SOCIETY FOR VASCULAR ULTRASOUND	$980,000	44	2003–2015
AMERICAN ELECTRIC POWER	$910,000	12	2007–2010
SPECIALTY & BIOTECH DISTRIBUTORS ASSOCATION	$900,000	15	2004–2010
CATALYST PAPER	$895,000	11	2015–2017
MONSANTO CO	$870,000	23	2002–2010
CORD BLOOD ASSOCIATION	$850,000	47	2015–2025
TAYLOR FRESH FOODS, INC	$850,000	8	2025–2026
RESOURCE MANAGEMENT SERVICE LLC	$820,000	14	2014–2017
ENCHANT ENERGY CORPORATION	$815,000	14	2020–2023
OWL ROCK CAPITAL PARTNERS	$785,000	13	2020–2022

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	1,472
SENATE	1,415
U.S. Trade Representative (USTR)	382
Centers For Medicare and Medicaid Services (CMS)	361
Treasury, Dept of	308
Commerce, Dept of (DOC)	300
Health & Human Services, Dept of (HHS)	228
State, Dept of (DOS)	179
White House Office	156
Food & Drug Administration (FDA)	123
Patent & Trademark Office (PTO)	120
Environmental Protection Agency (EPA)	111
Agriculture, Dept of (USDA)	104
Homeland Security, Dept of (DHS)	94
Office of Management & Budget (OMB)	78
Health Resources & Services Administration (HRSA)	53
Council on Environmental Quality (CEQ)	46
Justice, Dept of (DOJ)	43
Office of Science & Technology Policy (OSTP)	36
Federal Deposit Insurance Corporation (FDIC)	25

Top Issues Lobbied

Most frequently reported lobbying issues

Issue Code	Description	Reports
Trade (domestic/foreign)	Trade (domestic/foreign)	591
Health Issues	Health Issues	517
Medicare/Medicaid	Medicare/Medicaid	438
Financial Institutions/Investments/Securities	Financial Institutions/Investments/Securities	205
Banking	Banking	201
Environment/Superfund	Environment/Superfund	140
Science/Technology	Science/Technology	139
Budget/Appropriations	Budget/Appropriations	133
Copyright/Patent/Trademark	Copyright/Patent/Trademark	125
Energy/Nuclear	Energy/Nuclear	101
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	90
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	85
Tariff (miscellaneous tariff bills)	Tariff (miscellaneous tariff bills)	83
Agriculture	Agriculture	81
Telecommunications	Telecommunications	75
Food Industry (safety, labeling, etc.)	Food Industry (safety, labeling, etc.)	71
Economics/Economic Development	Economics/Economic Development	61
Consumer Issues/Safety/Products	Consumer Issues/Safety/Products	58
Defense	Defense	53
Manufacturing	Manufacturing	46

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1346119th Congress

To amend the Clean Air Act with respect to the ethanol waiver for Reid Vapor Pressure under that Act, and for other purposes.

2026 · third_quarter · Client: SMALL REFINERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1346, Nationwide Consumer and Fuel Retailer Choice Act of 2025

Client expense: — · Firm income: $20,000

Matched citations: H.R. 1346

H.R. 5160119th Congress

Stem Cell Therapeutic and Research Reauthorization Act of 2025

2026 · third_quarter · Client: DUKE UNIVERSITY MEDICAL CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act

Client expense: — · Firm income: —

Matched citations: H.R. 5160

H.R. 5160119th Congress

Stem Cell Therapeutic and Research Reauthorization Act of 2025

2026 · third_quarter · Client: DUKE UNIVERSITY MEDICAL CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act

Client expense: — · Firm income: —

Matched citations: H.R. 5160

H.R. 5160119th Congress

Stem Cell Therapeutic and Research Reauthorization Act of 2025

2026 · third_quarter · Client: DUKE UNIVERSITY MEDICAL CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act

Client expense: — · Firm income: —

Matched citations: H.R. 5160

Show 21 more cited filings

H.R. 1921119th Congress

Hearing Device Coverage Clarification Act

2026 · third_quarter · Client: ENVOY MEDICAL CORPORATION

Open original LDA filing ↗

Cited source text and reported amounts

Support for H.R. 1921/S. 983, the Hearing Device Coverage Clarification Act

Client expense: — · Firm income: $20,000

Matched citations: H.R. 1921

S. 983119th Congress

Hearing Device Coverage Clarification Act

2026 · third_quarter · Client: ENVOY MEDICAL CORPORATION

Open original LDA filing ↗

Cited source text and reported amounts

Support for H.R. 1921/S. 983, the Hearing Device Coverage Clarification Act

Client expense: — · Firm income: $20,000

Matched citations: S. 983

H.R. 1921119th Congress

Hearing Device Coverage Clarification Act

2026 · second_quarter · Client: ENVOY MEDICAL CORPORATION

Open original LDA filing ↗

Cited source text and reported amounts

Support for H.R. 1921/S. 983, the Hearing Device Coverage Clarification Act

Client expense: — · Firm income: —

Matched citations: H.R. 1921

S. 983119th Congress

Hearing Device Coverage Clarification Act

2026 · second_quarter · Client: ENVOY MEDICAL CORPORATION

Open original LDA filing ↗

Cited source text and reported amounts

Support for H.R. 1921/S. 983, the Hearing Device Coverage Clarification Act

Client expense: — · Firm income: —

Matched citations: S. 983

H.R. 5160119th Congress

Stem Cell Therapeutic and Research Reauthorization Act of 2025

2026 · second_quarter · Client: DUKE UNIVERSITY MEDICAL CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act

Client expense: — · Firm income: $10,000

Matched citations: H.R. 5160

H.R. 5160119th Congress

Stem Cell Therapeutic and Research Reauthorization Act of 2025

2026 · second_quarter · Client: DUKE UNIVERSITY MEDICAL CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act

Client expense: — · Firm income: $10,000

Matched citations: H.R. 5160

H.R. 5160119th Congress

Stem Cell Therapeutic and Research Reauthorization Act of 2025

2026 · second_quarter · Client: DUKE UNIVERSITY MEDICAL CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act

Client expense: — · Firm income: $10,000

Matched citations: H.R. 5160

H.R. 1346119th Congress

To amend the Clean Air Act with respect to the ethanol waiver for Reid Vapor Pressure under that Act, and for other purposes.

2026 · second_quarter · Client: SMALL REFINERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1346, Nationwide Consumer and Fuel Retailer Choice Act of 2025

Client expense: — · Firm income: $260,000

Matched citations: H.R. 1346

H.R. 1346119th Congress

To amend the Clean Air Act with respect to the ethanol waiver for Reid Vapor Pressure under that Act, and for other purposes.

2026 · second_quarter · Client: SMALL REFINERS OF AMERICA

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1346, Nationwide Consumer and Fuel Retailer Choice Act of 2025

Client expense: — · Firm income: —

Matched citations: H.R. 1346

H.R. 5160119th Congress

Stem Cell Therapeutic and Research Reauthorization Act of 2025

2026 · first_quarter · Client: DUKE UNIVERSITY MEDICAL CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act

Client expense: — · Firm income: $10,000

Matched citations: H.R. 5160

H.R. 5160119th Congress

Stem Cell Therapeutic and Research Reauthorization Act of 2025

2026 · first_quarter · Client: DUKE UNIVERSITY MEDICAL CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act

Client expense: — · Firm income: $10,000

Matched citations: H.R. 5160

H.R. 5160119th Congress

Stem Cell Therapeutic and Research Reauthorization Act of 2025

2026 · first_quarter · Client: DUKE UNIVERSITY MEDICAL CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act

Client expense: — · Firm income: $10,000

Matched citations: H.R. 5160

H.R. 5160119th Congress

Stem Cell Therapeutic and Research Reauthorization Act of 2025

2026 · first_quarter · Client: DUKE UNIVERSITY MEDICAL CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Federal funding for NCBI, H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act

Client expense: — · Firm income: —

Matched citations: H.R. 5160

H.R. 5160119th Congress

Stem Cell Therapeutic and Research Reauthorization Act of 2025

2026 · first_quarter · Client: DUKE UNIVERSITY MEDICAL CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Federal funding for NCBI, H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act

Client expense: — · Firm income: —

Matched citations: H.R. 5160

H.R. 5160119th Congress

Stem Cell Therapeutic and Research Reauthorization Act of 2025

2026 · first_quarter · Client: DUKE UNIVERSITY MEDICAL CENTER

Open original LDA filing ↗

Cited source text and reported amounts

Federal funding for NCBI, H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act

Client expense: — · Firm income: —

Matched citations: H.R. 5160

H.R. 2864118th Congress

Countering CCP Drones Act

2025 · third_quarter · Client: DJI TECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2864, the Countering CCP Drones Act and other issues related to the regulation of drones.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2864

H.R. 2864118th Congress

Countering CCP Drones Act

2025 · third_quarter · Client: DJI TECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2864, the Countering CCP Drones Act and other issues related to the regulation of drones.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2864

H.R. 2864118th Congress

Countering CCP Drones Act

2025 · third_quarter · Client: DJI TECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2864, the Countering CCP Drones Act and other issues related to the regulation of drones.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2864

H.R. 2864118th Congress

Countering CCP Drones Act

2025 · third_quarter · Client: DJI TECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2864, the Countering CCP Drones Act and other issues related to the regulation of drones.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 2864

H.R. 2864118th Congress

Countering CCP Drones Act

2025 · second_quarter · Client: DJI TECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2864, the Countering CCP Drones Act and other issues related to the regulation of drones.

Client expense: — · Firm income: $120,000

Matched citations: H.R. 2864

H.R. 2864118th Congress

Countering CCP Drones Act

2025 · second_quarter · Client: DJI TECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2864, the Countering CCP Drones Act and other issues related to the regulation of drones.

Client expense: — · Firm income: $120,000

Matched citations: H.R. 2864

Source: Senate LDA

SIDLEY AUSTIN LLP — Lobbying Disclosure | Poliscope